Table 2
From the following article
Antivirals become a broader enterprise
Jeffrey L Fox
Nature Biotechnology 25, 1395 - 1402 (2007)
doi:10.1038/nbt1207-1395
Table 2. Selected companies with antivirals in preclinical development
| Company | Antiviral approach | Target virus |
|---|---|---|
| AVI Biopharma (Portland, OR) | Antisense | Ebola, Marburg |
| CytoDyn (Sante Fe, NM) | DNA vaccine | Influenza |
| Functional Genetics (Gaithersburg, MD) | mAb targets 'hijacked' cell protein (TSG101) | Multiple targets |
| Isis Pharmaceuticals (Carlsbad, CA) | Oligonucleotide aptamer | HIV |
| Presidio (San Francisco, CA) | Viral genome nuclear import blocker | HIV |
| Regulus (Carlsbad, CA) | microRNA | HCV, others |
| REPLICor (Laval, Quebec, Canada) | Amphipathic DNA polymers | HCV |
| Sangamo BioSciences (Richmond, CA) | Zinc-finger nucleases | CCR5 receptor/HIV |
| SIGA Technologies (New York, NY) | Viral particle blocker | Lassa |
| Symphogen (Lyngby, Denmark) | Polyclonal antibodies | RSV, vaccinia |
| Tacere Therapeutic (San Jose, CA) | Short hairpin RNA (shRNA) | HCV |